Biopharma’s increasing demand for complex kit assembly drives Almac expansion

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/NikiLitov)
(Image: Getty/NikiLitov)
Almac Group has expanded its commercial packaging capabilities to meet a “significant increase” in demand for complex kit assembly as biopharma brings more advanced sterile and biological products to the market, says CDMO.

The contract pharmaceutical development and manufacturing organization (CDMO) has added a new semi-automated packaging system (SAPS) at its Audubon, PA facility.

According to the company, the SAPS line can process both standard and custom syringes, as well as auto-injector pens and other medical devices. The technology can operate on various scales and vision systems provide 100% automated verification and rejection of all components.

“We have witnessed a significant increase in the demand for complex kit assembly as biopharma companies are seeking to provide dose-specific or even combination product packages,” ​said Adam Schroeder, Almac Pharma Services director of business development.

Companies are also looking to simplify the drug administration process for patients and caregivers, “by providing a self-contained kit of all the necessary components, as opposed to individual components from multiple suppliers,” ​Schroeder told us.

Schroeder said the company is currently providing kit assembly for a number of clients, each with bespoke requirements, including auto-injector pen kitting for the diabetes market and complex kits for epilepsy treatment.

“We expect the demand for this form of specialized packaging to increase as biopharma companies bring more advanced sterile and biological products with parenteral delivery forms to the market,” ​he added.

Related news

Show more

Related products

show more

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-Jun-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

Why Blister Packaging: Things to Consider

Why Blister Packaging: Things to Consider

Catalent Pharma Solutions | 03-Dec-2020 | Insight Guide

The decision to use blister packaging for either clinical trials or commercial drug manufacturing comes with a host of factors to consider. Pharmaceutical...

Related suppliers

Follow us


View more